Additionally, glycine has been suggested as a prognostic biomarker in studies comparing tissue samples from patients with a poor or good prognosis based on clinical parameters (lymphatic spread, tumor size and hormone receptor status) [39,72], where high glycine levels were associated with a poor prognosis. Here, NR4A1 is linked to neoplasm.